Company Profile

NewLink Genetics Corporation (AKA:New Link Genetics Inc~NewLink~BioProtection Systems Corp)
Profile last edited on: 5/25/17      CAGE: 47WH4      UEI:

Business Identifier: Cancer vaccines and drugs that modulate the immune system
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2901 South Loop Drive Suite 5100
Ames, IA 50010
   (515) 296-5555
Location: Multiple
Congr. District: 04
County: Story

Public Profile

Headquartered in Ames, IA but with facilities in Devens MA and Austin, TX, NewLink Genetics Corporation, a biopharmaceutical company, focuses on immunotherapeutic products for the treatment of cancer. The firm's portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia. The company’s HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Charles J Link -- Co-Founder, Chair, CEO and CSO

  S Carroll

  Christopher L Karp

  Eugene P Kennedy -- Vice President for Clinical and Medical Affairs

  Gordon H Link Jr -- Chief Financial Officer

  Kenneth Lynn -- Senior Vice President of Business Development

  Mario Mautino -- Vice President: Drug Discovery

  Marilyn Moehlmann

  Nicholas N Vahanian -- Chief Medical Officer

  Brian Wiley -- Chief Commercial Officer

  Won-Bin Young

  Jun Zhao -- Vice President:Quality and Compliance